Iomedico Ag

This study is observing 50 patients with relapsed or refractory multiple myeloma who are taking melflufen plus dexamethasone as a later-line treatment. The goal is to see how well the drug controls the disease in routine medical practice, outside of a controlled trial. Researcher…

This study is tracking 100 adults with a rare and aggressive bile duct cancer that has a specific IDH1 gene mutation. Participants will take the targeted drug ivosidenib, which was recently approved in Europe. Researchers will monitor how long the cancer stays under control, over…

This study is observing how well the drug fruquintinib works for people with metastatic colorectal cancer who have already tried standard treatments. About 150 participants in Germany will be treated as part of their normal care, and researchers will track tumor response, surviva…

This study follows about 200 adults with polycythemia vera (a blood disorder) who do not have an enlarged spleen and are starting treatment with ropeginterferon alfa-2b. Researchers will track symptoms, blood cell counts, and side effects over 36 months in real-world clinics. The…

This study follows 500 postmenopausal women with advanced ER+ HER2- breast cancer that has an ESR1 mutation. Participants receive elacestrant as part of their normal care. Researchers will track quality of life, side effects, and how the cancer responds over time. The goal is to …

The JADE study is a large registry that will follow 1,000 people with liver or bile duct cancer in Germany. Its goal is to collect information on how these cancers are actually treated in routine care, including treatments, outcomes, and patient quality of life. No experimental d…

This study is following over 6,000 breast cancer patients in Germany to see what treatments they actually receive in routine care and how they fare over time. Researchers are collecting data on treatment patterns, survival, and quality of life from patients with early and advance…

This study is following 200 people in Germany who have myelofibrosis (a type of bone marrow cancer) and anemia (low red blood cells). Researchers will track which treatments patients receive, how their disease responds, and how they feel over time. The goal is to gather real-worl…

This study is a large registry that will follow nearly 3,000 people with blood cancers like chronic lymphocytic leukemia and several types of lymphoma. Researchers will collect information on treatments, how the disease progresses, and patients' quality of life over time. The goa…

This study is a large German registry that will follow nearly 2,000 people with advanced ovarian or endometrial cancer. Researchers will collect information on the treatments patients actually receive, how their disease responds, and their quality of life. The goal is to understa…

This study is a large registry that will collect information from about 1,900 people with advanced cancer of the esophagus or stomach who are receiving palliative treatment in Germany. The goal is to understand what treatments are actually used in everyday practice and how patien…

This study is a large registry that will follow 2200 people with multiple myeloma in Germany. Its goal is to collect information on the types of treatments patients actually receive, how well they work, and how patients feel over time. Participants will provide medical data and o…

This study follows 150 adults with slow-growing IDH-mutant grade 2 gliomas who are taking vorasidenib after surgery. Researchers will track quality of life, seizures, and tumor response in routine German clinics. The goal is to see how well the drug works outside of strict trial …

This study is a large registry that will follow nearly 2,000 people with advanced kidney or bladder cancer in Germany. Researchers will collect information on the treatments patients actually receive, how well they work, and patients' quality of life. The goal is to understand re…

This study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib (with or without obinutuzumab). Researchers will track hospital visits, quality of life, and how well the d…